Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)
| ClinicalTrials.gov Identifier |
| NCT04566133 |
| Institution Name |
| National Cancer Institute |
| Institution Address (Street) |
| 10 Center Drive |
| Institution City |
| Bethesda |
| Institution State |
| Maryland |
| Institution ZIP Code |
| 20892 |
| Institution Country |
| United States |
| Institution Phone |
| (240) 858-3155 |
| Institution Website |
| https://ccr.cancer.gov/staff-directory/tim-f-greten |
| Principal Investigator |
| Tim Greten |
| Principal Investigator Phone |
| (240) 760-6114 |
| Principal Investigator Email |
| tim.greten@nih.gov |
| Study Coordinator |
| Donna Mabry |
| Study Coordinator Phone |
| (240) 858-3155 |
| Study Coordinator Email |
| donna.mabry@nih.gov |
| Study Overview |
| We test a combination of trametinib and hydroxychloroquine (HCQ) as systemic treatment in patients with KRAS mutated bile duct cancer. Treatment is free at NIH. Travel costs will be paid for. |
| Enrollment Information |
| Open |
| Study Start Date |
| 20210715 |
| Study End Date |
| 20221231 |
| Study Purpose |
|
| Inclusion Criteria |
|
| Exclusion Criteria |
|
| Financial Assistance Available |
| Yes |